Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Unigene Laboratories, a biopharmaceutical company engaged in the oral and nasal delivery of peptide drugs, has reported a net loss of $2.34 million, or $0.03 per share, for the fourth quarter ended December 31, 2008, compared to a net loss of $1.67 million, or $0.02 per share, for the fourth quarter ended December 31, 2007.
Subscribe to our email newsletter
Net loss for the year ended December 31, 2008 was $6.08 million, or $0.07 per share, compared to a net loss of $3.45 million, or $0.04 per share, for the year ended December 31, 2007.
Revenue for the three months ended December 31, 2008 was $4.85 million, compared to $3.03 million for the three months ended December 31, 2007. For the year ended December 31, 2008, the company reported revenues of $19.23 million, compared to $20.42 million for the year ended December 31, 2007.